CompletedNCT06496750
Ketamine study for methamphetamine use concerns
About this title
Read the official source — NCT06496750Medication studyAges 18–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- San Leandro and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 11, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 120
- Sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06496750
- Official title
Show the full official title
NIDA CTN-0132 Randomized, Double-Blind, Active Placebo-Controlled Trial of Ketamine for Methamphetamine Use Disorder (KMD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
San Leandro · Albuquerque · New York
2 more locations
- Greenville
- Dallas
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Texas Southwestern Medical Center, a university.
Did this study involve medication?
Yes. The study involved medication, including Ketamine Hydrochloride and Midazolam Hydrochloride.
Who was this study for?
Listed age limits: 18 years to 65 years.
